<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499668</url>
  </required_header>
  <id_info>
    <org_study_id>VICC SUPP 0513</org_study_id>
    <secondary_id>VU-VICC-SUPP-0513</secondary_id>
    <secondary_id>VU-VICC-IRB-070193</secondary_id>
    <secondary_id>MERCK-VU-VICC-SUPP-0513</secondary_id>
    <nct_id>NCT00499668</nct_id>
  </id_info>
  <brief_title>Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer</brief_title>
  <official_title>A Pilot Study of Aprepitant Versus Ondansetron for the Treatment of Opioid Induced Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Antiemetic drugs, such as aprepitant and ondansetron, may help lessen nausea and
      vomiting caused by opioids. It is not yet known whether aprepitant is more effective than
      ondansetron in treating nausea and vomiting caused by opioids in patients with cancer.

      PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works
      compared to ondansetron in treating nausea and vomiting caused by opioids in patients with
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To evaluate the efficacy of aprepitant as monotherapy for opioid-induced nausea and
           vomiting (OINV) in comparison to ondansetron hydrochloride in patients who have failed
           at least one prior anti-emetic agent/regimen.

      Secondary

        -  To determine whether control of OINV improves quality of life.

        -  To determine if control in OINV decreases pain.

        -  To determine if control in OINV improves mood.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

        -  Arm A: Patients receive aprepitant orally once daily for 7 days in the absence of
           unacceptable toxicity or persistent grade 4 nausea and vomiting.

        -  Arm B: Patients receive ondansetron hydrochloride orally 3 times daily for 7 days in the
           absence of unacceptable toxicity or persistent grade 4 nausea and vomiting.

      Patients complete the following questionnaires: Functional Assessment of Cancer
      Therapy-General (FACT-G); Center for Epidemiologic Studies Depression Scale (CES-D); and
      Brief Pain Index (BPI) at baseline and on day 7. Patients also complete symptom diaries
      documenting the following: number of episodes (an emetic episode is defined as a simple vomit
      or retch, or any number of continuous vomits or retches; distinct episodes that are separated
      by at least 1 minute) of vomiting or retching including the date and time; worst and average
      degree of nausea (recorded every 2 hours while awake during the first 24 hours after
      treatment and every 8 hours on days 1-7); and adverse events other than episodes of vomiting
      and nausea.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    slow accrual
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of nausea and vomiting</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain control</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global satisfaction</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Nausea and Vomiting</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>125 mg orally for 7 days</description>
    <arm_group_label>ARM A</arm_group_label>
    <other_name>EMEND</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron hydrochloride</intervention_name>
    <description>24 mg orally for 7 days</description>
    <arm_group_label>ARM B</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  History of malignancy (including hematological malignancies)

          -  Has pain requiring opioid analgesics

          -  Nausea and vomiting (associated with opioid analgesic use) that is unrelieved by at
             least one standard antiemetic regimen (including 5HT3 antagonist and dexamethasone
             combination therapy)

               -  Patients who have failed ondansetron hydrochloride for treatment of
                  opioid-induced nausea and vomiting will be excluded from the study

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Able to assess severity of nausea and vomiting and document it in the diary

          -  Women must not be pregnant or lactating

          -  Women of childbearing potential and sexually active males are strongly advised to use
             an accepted and effective method of contraception

          -  Urine pregnancy test will be given to women of childbearing age

          -  No concerns about compliance with medication regimen or medical follow-up (patient
             must be able to tolerate oral dosing)

          -  No severe or chronic illness or other causes of nausea and vomiting, that in judgment
             of the treating physician, will place patient at risk

          -  No severe gastrointestinal obstruction or active peptic ulcer disease

          -  Serum ALT and AST &lt; 2 times upper limit of normal (ULN)

          -  Serum bilirubin &lt; 2 times ULN

          -  Serum alkaline phosphatase &lt; 2 times ULN

        PRIOR CONCURRENT THERAPY:

          -  No surgery within the past 7 days

          -  No chemotherapy within the past 7 days

          -  No total or lower body radiation therapy within the past 7 days

          -  Patient may not be scheduled to undergo total body irradiation or lower body
             irradiation, chemotherapy, or surgery during study participation

          -  Patient must not be taking warfarin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara A. Murphy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <last_update_submitted>March 29, 2013</last_update_submitted>
  <last_update_submitted_qc>March 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Barbara Murphy, MD</investigator_full_name>
    <investigator_title>Professor of Medicine; Director, Cancer Supportive Care Program; Director, Head and Neck Research Program; Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>nausea and vomiting</keyword>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>adult acute lymphoblastic leukemia</keyword>
  <keyword>adult acute myeloid leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>mast cell leukemia</keyword>
  <keyword>adult T-cell leukemia/lymphoma</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>hairy cell leukemia</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>AIDS-related lymphoma</keyword>
  <keyword>adult Hodgkin lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>mycosis fungoides/Sezary syndrome</keyword>
  <keyword>adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>adult Burkitt lymphoma</keyword>
  <keyword>adult diffuse large cell lymphoma</keyword>
  <keyword>adult diffuse mixed cell lymphoma</keyword>
  <keyword>adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>adult immunoblastic large cell lymphoma</keyword>
  <keyword>adult lymphoblastic lymphoma</keyword>
  <keyword>grade 1 follicular lymphoma</keyword>
  <keyword>grade 2 follicular lymphoma</keyword>
  <keyword>grade 3 follicular lymphoma</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>small lymphocytic lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>primary central nervous system lymphoma</keyword>
  <keyword>post-transplant lymphoproliferative disorder</keyword>
  <keyword>multiple myeloma and other plasma cell neoplasms</keyword>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>chronic myeloproliferative disorders</keyword>
  <keyword>myelodysplastic/myeloproliferative diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

